Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 is also expressed on Tregs; targeting CTLA-4 could theoretically lead to Treg cell dysfunction or depletion as has been demonstrated in mice (Simpson et al., 2013), though not all data support this notion in humans”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The lack of additive or synergistic therapeutic benefit of the combination of –CTLA-4 with peptide vaccination in the recent phase III clinical trial (Hodi et al., 2010) could at least be partially explained by a lack of vaccine-mediated impact on appropriate accessory cell populations.”
BackgroundInfluentialSelf-citationFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“–CTLA-4 therapy has demonstrated significant antitumor activity in preclinical tumor models (Leach et al., 1996; van Elsas et al., 1999; Quezada et al., 2011) and in clinical trials as an immunotherapy for metastatic melanoma (Hodi et al., 2010; Robert et al., 2011).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“, 2001), the demonstration that CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et a…”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 14×
“In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
BackgroundInfluentialSelf-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 1×
“…CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et al., 2008).”
BackgroundRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
Background
Cited by
Items 501–600 of 1,000
Mattiuz, R., Brousse, C., Ambrosini, M., Cancel, J.-C., Bessou, G., Mussard, J., Sanlaville, A., Caux, C., Bendriss‐Vermare, N., Valladeau‐Guilemond, J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1305 · Cited by 65
Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity
Kennedy, P. T., Saulters, E. L., Duckworth, A. D., Lim, Y. J., Woolley, J. F., Slupsky, J. R., Cragg, M. S., Ward, F. J., & Dahal, L. N. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.028 · Cited by 67
“These include deletion of intratumoral T reg cells, 12 modulation of T cell receptor (TCR)-CD28 interaction, 13 and regulating naive T cell activation and differentiation.”
Wieland, A., Shashidharamurthy, R., Kamphorst, A. O., Han, J., Aubert, R. D., Choudhury, B., Stowell, S. R., Lee, J., Punkosdy, G. A., Shlomchik, M. J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.009 · Cited by 65
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 65
“variability in toxicity incidence remain undefined, but may include Fc-dependent recognition of bound ICI on immunosuppressive regulatory T-cells (Tregs), which have higher expression of CTLA-4, leading to their depletion (Figure 1, v).(27) IrAEs generally occur within the first 3–6 months when using CTLA-4 or PD-1/PD…”
BackgroundImmune Privilege: The Microbiome and Uveitis
Mölzer, C., Heissigerová, J., Wilson, H. M., Kuffová, L., & Forrester, J. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608377 · Cited by 73
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy
Williams, G. S., Mistry, B., Guillard, S., Ulrichsen, J. C., Sandercock, A. M., Wang, J., Gonzalez-Munoz, A. L., Parmentier, J. M., Black, C. M., Soden, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11943 · Cited by 62
“Antibodies and related molecules can enhance the immune response to cancer either through antagonism of immunosuppressive molecules, such as anti-CTLA-4 or PD-1 mAbs, through agonist activity, as previously described for mAbs targeting TNFRSF family members including GITR, OX40, CD40, and 4-1BB [41], or by depleting s…”
BackgroundBostwick, A. D., Salama, A. K., & Hanks, B. A. (2015) · Journal for Immunotherapy of Cancer · doi:10.1186/s40425-015-0064-2 · Cited by 59
“While ipilimumab has been demonstrated to effectively promote the activation of effector CD8 T cells, recent studies have revealed this agent to also deplete regulatory T cell populations which contribute to the establishment of an immunotolerant tumor microenvironment [2,3].”
BackgroundSuppression of T cell responses in the tumor microenvironment
Frey, A. B. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.096 · Cited by 61
“MDSC modulate the function of various mmune cells: natural killer (NK) cells, macrophage, Treg, and T ells, generally acting to suppress cell activation, including inducion of apoptosis.”
BackgroundInfluentialCuring Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Dai, M., Yip, Y. Y., Hellström, I., & Hellström, K. E. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1339 · Cited by 64
Hutmacher, C., Núñez, N. G., Liuzzi, A. R., Becher, B., & Neri, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0566 · Cited by 60
“, 9H10, IgG1SDALIE a mutated antibody with high binding affinity to CD16a) may be more effective than 4F10 and 9D9 in eradicating Tregs via an antibody-dependent cell-cytotoxicity mechanism (44,45).”
BackgroundToxicity Patterns With Immunomodulating Antibodies and Their Combinations
Haanen, J. B. A. G., van Thienen, J. V., & Blank, C. U. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.011 · Cited by 64
Chand, D. S., Savitsky, D. A., Krishnan, S., Mednick, G., Delepine, C., García‐Broncano, P., Soh, K. T., Wu, W., Wilkens, M. K., Udartseva, O. O., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0190 · Cited by 63
“…efficacy studies in tumor-bearing mouse models suggested that α CTLA-4 activity was partly dependent on Fc-mediated intratumoral Treg depletion (8, 32), those studies utilized mouse IgG2a backbones that poorly predict human IgG1 performance and might not represent human conventional IgG1 α CTLA-4…”
Waight, J. D., Takai, S., Marelli, B., Qin, G., Hance, K. W., Zhang, D., Tighe, R., Lan, Y., Lo, K.-M., Sabzevari, H., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402725 · Cited by 59
Turning the Tide Against Regulatory T Cells
Han, S., Toker, A., Liu, Z. Q., & Ohashi, P. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00279 · Cited by 60
Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment
Zhang, F.-P., Huang, Y., Luo, W., Deng, W., Liu, C., Xu, L., & Liu, C. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i2.134 · Cited by 62
Chen, X., Liu, X., Ding, X., Zhang, J., Jiang, L., Liu, S., Hou, H., Jiang, B., Cheng, L., Zhu, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828319 · Cited by 59
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level
Grenier, J. M., Yeung, S. T., & Khanna, K. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00610 · Cited by 58
Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways
Weitzenfeld, P., Bournazos, S., & Ravetch, J. V. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128437 · Cited by 59
“Previous studies have focused on antibodies targeting tumor-associated proteins, such as CD20 (9) and Her2/Neu (10), as well as antibodies targeting the checkpoint targets CTLA4 (11), CD40 (12), and PD-1/PD-L1 (13), establishing the mechanistic role by which such antibodies confer their therapeutic activity in vivo th…”
BackgroundSelf-citationHarnessing neoantigen specific CD4 T cells for cancer immunotherapy
Brightman, S. E., Naradikian, M. S., Miller, A. M., & Schoenberger, S. P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0220-603rr · Cited by 62
Immunotherapy for Prostate Cancer
Venturini, N. J., & Drake, C. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030627 · Cited by 61
Watanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 60
Lax, B. M., Palmeri, J. R., Lutz, E. A., Sheen, A. M., Stinson, J. A., Duhamel, L., Santollani, L., Kennedy, A., Rothschilds, A. M., Spranger, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300895120 · Cited by 61
“The lack of therapeutic efficacy of 9d9 LALA-PG, the construct capable of antagonism only, leaves no doubt that Treg depletion is essential for efficacy in this system, confirming previous reports (63–67).”
Tumour-associated macrophage polarisation and re-education with immunotherapy
Josephs, D. H. (2015) · Frontiers in Bioscience · doi:10.2741/e735 · Cited by 57
“This supports the potential of antibodies to activate patient effector cells including tumour-polarized macrophages (65, 71, 73).”
Patel, M. A., Kim, J. E., Theodros, D., Tam, A. J., Velarde, E., Kochel, C. M., Francica, B. J., Nirschl, T. R., Ghasemzadeh, A., Mathios, D., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0132-2 · Cited by 59
“Nevertheless, our findings imply that depleting antibodies dependent upon Fc γ R interactions, such as anti-CTLA-4 or anti-OX40, may not be of clinical value in brain cancer if the appropriate Fc γ R are also absent from human microglia [40, 41].”
BackgroundSurface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 75
“antibody-dependent cell-mediated cytotoxicity by Fcγ receptor-expressing macrophages within the tumor microenvironment (22).”
BackgroundAn innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides
Eggink, L. L., Roby, K. F., Cote, R., & Hoober, J. K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0339-5 · Cited by 60
“Activation of the phagocytic activity of macrophages leads to reduction of TREG cells in melanoma tumors [92, 93].”
BackgroundCharacterization and Comparison of GITR Expression in Solid Tumors
Vence, L. M., Bucktrout, S. L., Curbelo, I. F., Blando, J. M., Smith, B. M., Mahne, A. E., Lin, J. C.-Y., Park, T., Pascua, E., Sai, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0289 · Cited by 58
Self-citationTherapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 62
Hamdan, F., Ylösmäki, E. O., Chiaro, J., Giannoula, Y., Long, M., Fusciello, M., Feola, S., Martins, B., Feodoroff, M., Antignani, G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003000 · Cited by 57
Matoba, T., Imai, M., Ohkura, N., Kawakita, D., Ijichi, K., Toyama, T., Morita, A., Murakami, S., Sakaguchi, S., & Yamazaki, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.32024 · Cited by 59
Strategies to overcome DC dysregulation in the tumor microenvironment
Mestrallet, G., Sone, K., & Bhardwaj, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980709 · Cited by 57
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 57
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients
Tobin, R. P., Davis, D. M., Jordan, K. R., & McCarter, M. D. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1016-449r · Cited by 57
Hendriks, D., Choi, G., de Bruyn, M., Wiersma, V. R., & Bremer, E. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2016.10.002 · Cited by 67
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
Teige, I., Mårtensson, L., & Frendéus, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00481 · Cited by 59
Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer
Xie, M., Wei, J., & Xu, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00676 · Cited by 60
The immune escape in melanoma: role of the impaired dendritic cell function
Tucci, M., Stucci, L. S., Passarelli, A. M., Giudice, G., Dammacco, F., & Silvestris, F. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.955851 · Cited by 55
“Recent pre-clinical and clinical studies suggest that CTLA-4 blockade directly activates CD4 and CD8 T-cells, whereas the effect on Tregs in patients with melanoma is still controversial since either a dose-dependent expansion of Foxp3 population or their expansion by CTLA-4 MoAbs has been demonstrated [80,81].”
BackgroundA New VISTA on combination therapy for negative checkpoint regulator blockade
Deng, J., Mercier, I. L., Kuta, A., & Noelle, R. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0190-5 · Cited by 57
“However, anti-CTLA-4 activity has also been linked to Fc mediated Treg depletion at the tumor site by tumor infiltrating macrophages [23, 24].”
BackgroundTCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis
Holt, M. P., Punkosdy, G. A., Glass, D. D., & Shevach, E. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601670 · Cited by 59
Hui, E. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201810035 · Cited by 56
Immune checkpoints and cancer development: Therapeutic implications and future directions
Mehdizadeh, S., Bayatipoor, H., Pashangzadeh, S., Jafarpour, R., Shojaei, Z., & Motallebnezhad, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153485 · Cited by 56
Sia, J., Hagekyriakou, J., Chindris, I., Albarakati, H., Leong, T., Schlenker, R., Keam, S. P., Williams, S., Neeson, P. J., Johnstone, R. W., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.05.014 · Cited by 56
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data
Wassmer, C., Hajji, S. E., Papazarkadas, X., Compagnon, P., Tabrizian, P., Lacotte, S., & Toso, C. (2023) · Cancers · doi:10.3390/cancers15184574 · Cited by 57
“They can reduce the function and expansion of CD4 and CD8 T cells, B cells, natural killer cells, and APCs, and their presence in tumor tissue is associated with poorer oncological outcomes [42].”
The role of CD4+ T cells in tumor and chronic viral immune responses
Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 62
The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment
Nelson, D. J., Fisher, S. A., & Robinson, B. W. S. (2014) · Journal of Immunology Research · doi:10.1155/2014/789069 · Cited by 61
D’Aloia, M. M., Caratelli, S., Palumbo, C., Battella, S., Arriga, R., Lauro, D., Palmieri, G., Sconocchia, G., & Alimandi, M. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.10.014 · Cited by 57
“These mechanisms, including the complement-dependent cytotoxicity [5,6], contribute to the positive outcome of mAb-based immunotherapy [7,8].”
BackgroundHalpert, M. M., Konduri, V., Liang, D., Chen, Y., Wing, J. B., Paust, S., Levitt, J. M., & Decker, W. K. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0009 · Cited by 57
“More recent data suggest that ipilimumab might also deplete the regulatory T-cell subset in an Fc-dependent manner through ADCC [47,48].”
Heidegger, S. M., Kreppel, D., Bscheider, M., Stritzke, F., Nedelko, T., Wintges, A., Bek, S., Fischer, J. C., Graalmann, T., Kalinke, U., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.056 · Cited by 58
The Current Landscape of Antibody-based Therapies in Solid Malignancies
Shah, A., Rauth, S., Aithal, A., Kaur, S., Ganguly, K., Orzechowski, C., Varshney, G. C., Jain, M., & Batra, S. K. (2021) · Theranostics · doi:10.7150/thno.52614 · Cited by 49
“It is important to note that this work, along with many previous studies, assumes the presence of effector cells expressing higher levels of activating FcγR in infiltrating immune cell population to induce ADCC and Treg depletion [85, 129, 130].”
ResultHong, M. M. Y., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14061580 · Cited by 55
“Conversely, anti-CTLA-4 constructs with enhanced FcR binding affinity exhibit enhanced anti-tumor activity and Treg depletion [26,28,63].”
BackgroundInfluentialCombinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Yamazaki, N., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Kiyohara, Y., Tsutsumida, A., Namikawa, K., Okuyama, R., Otsuka, Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2870-0 · Cited by 53
Koguchi, Y., Hoen, H. M., Bambina, S., Rynning, M. D., Fuerstenberg, R. K., Curti, B. D., Urba, W. J., Milburn, C. M., Bahjat, F. R., Korman, A. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2303 · Cited by 59
Enhancement of Immune Effector Functions by Modulating IgG’s Intrinsic Affinity for Target Antigen
Mazor, Y., Yang, C., Borrok, M. J., Ayriss, J. E., Aherne, K., Wu, H., & Dall’Acqua, W. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157788 · Cited by 54
Targeting Immunotherapy to the Tumor Microenvironment
Dougan, M., & Dougan, S. K. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26005 · Cited by 54
Cancer vaccines: translation from mice to human clinical trials
Maeng, H. M., Terabe, M., & Berzofsky, J. A. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.001 · Cited by 57
Soldevilla, M. M., Villanueva, H., Meraviglia-Crivelli, D., Menon, A. P., Ruiz, M., Cebollero, J., Villalba-Esparza, M., Moreno, B., Lozano, T., Llópiz, D., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.013 · Cited by 53
“Other findings indicate that anti-CTLA-4 antibodies with immunoglobulin G2a (IgG2a) murine isotope or IgG1 human isotope could trigger depletion of tumor-infiltrating Tregs in some instances.(6,14,25) A recent publication claims that ipilimumab actually does not deplete tumor Tregs in spite of being humanized with IgG…”
BackgroundMethodJung, K., Kim, J.-A., Kim, Y., Lee, H. W., Kim, C.-H., Haam, S., & Kim, Y. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0143 · Cited by 55
“4A and B), in line with previous results (8).”
BackgroundResultDefining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 64
Gan, X., Shan, Q., Li, H., Janssens, R., Shen, Y., He, Y., Chen, F., van Haperen, R., Drabek, D., Li, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200879119 · Cited by 56
“Tumor regression was shown to be associated with an increase in the intratumoral Teff to Treg cell ratio, due to an expansion of Teff cells and selective depletion of Treg cells (18, 19).”
BackgroundNovel immunotherapies for hematologic malignancies
Nelson, M. H., & Paulos, C. M. (2014) · Immunological Reviews · doi:10.1111/imr.12245 · Cited by 57
“Indeed, in melanoma mouse models, CTLA-4 blockade was found to augment effector CD8 T cells by depleting Tregs via Fcc-macrophage mediated events (80).”
BackgroundIL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation
Sim, G. C., Liu, C., Wang, E., Liu, H., Creasy, C., Dai, Z., Overwijk, W. W., Roszik, J., Marincola, F., Hwu, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0195 · Cited by 49
“This is a critical point considering the toxicity of anti–CTLA-4 therapy and the demonstrated mechanism of action of anti–CTLA-4 in depleting Treg in patients and mouse models (29).”
BackgroundNeurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
Garcia, C. A., El-Ali, A., Rath, T. J., Contis, L. C., Gorantla, V. C., Drappatz, J., & Davar, D. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0393-z · Cited by 52
“Exact mechanisms underlying CTLA-4 inhibitor toxicity remain unclear, although multiple hypotheses including loss of peripheral tolerogenic mechanisms via T-regulatory cell depletion [36, 37] and atypical expression of CTLA-4 on non-immune cells [11] have been advanced.”
BackgroundImpact of the microbiome on cancer progression and response to anti-cancer therapies
Rosean, C. B., Feng, T.-Y., Azar, F. N., & Rutkowski, M. R. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.005 · Cited by 55
“Two landmark papers in Science provided the first evidence that alterations in commensal gut bacteria could influence responses to checkpoint blockade through CTLA-4 and PD-1 (Sivan et al., 2015; Vetizou et al., 2015).”
BackgroundInfluentialRe-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 54
Chen, L., Sun, R., Xu, J., Zhai, W., Zhang, D., Yang, M., Yue, C., Chen, Y., Li, S., Turnquist, H. R., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-1024 · Cited by 57
“This was consistent with previous findings that PD-1 is involved in the generation and maintenance of induced Tregs, as well as in homeostasis of natural Tregs (32).”
BackgroundResultInfluentialProgrammed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function
Araki, K., Youngblood, B., & Ahmed, R. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.019869 · Cited by 55
“CTLA-4 is also found on Tregs and plays an essential role in inhibitory functions of Tregs (Wing et al. 2008).”
BackgroundInfluentialImmunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 55
“This would lead to an increase in the intra-tumoral Teff/Treg ratio (10) and suggested a predominant trans mechanism.”
BackgroundAcquired resistance to cancer immunotherapy
Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 52
Lin, E., Liu, X., Liu, Y., Zhang, Z., Xie, L., Tian, K., Liu, J., & Yu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653358 · Cited by 59
“In addition, an animal model study found that exhaustion of Tregs could improve the therapeutic response of ICIs (80).”
Zhou, L., Velegraki, M., Wang, Y., Mandula, J. K., Chang, Y., Liu, W., Song, N., Kwon, H., Xiao, T., Bolyard, C. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180080 · Cited by 56
“…strongly correlates with clinical benefit in diverse cancer types, and Treg-directed therapy has been postulated as a promising anticancer therapy (7–10). gp96/GRP94 is an endoplasmic reticulum (ER) master chaperone for various proteins including TLRs, integrins, and glycoprotein A repetitions…”
BackgroundHansen, G. L., Gaudernack, G., Brunsvig, P. F., Cvancarova, M., & Kyte, J. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1766-5 · Cited by 52
Kinder, M., Greenplate, A. R., Strohl, W. R., Jordan, R. E., & Brezski, R. J. (2015) · mAbs · doi:10.1080/19420862.2015.1022692 · Cited by 55
Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)
Malas, S., Harrasser, M., Lacy, K. E., & Karagiannis, S. N. (2014) · Oncology Reports · doi:10.3892/or.2014.3275 · Cited by 53
“Future studies may also provide further insights into the pathways associated with immune cell activation and re-direction in patient circulation and tumour microenvironments (11,14,15,62,108).”
BackgroundTaylor, R. P., & Lindorfer, M. A. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.092684 · Cited by 50
“…receptor 2), also directly or indirectlymake use of effectormechanismsmediated by cells that express Fcg receptors (Zhang et al., 2007; Musolino et al., 2008; Taylor et al., 2009; Botta et al., 2012; Bulliard et al., 2013; Kim andAshkenazi, 2013; Simpson et al., 2013; Bianchini and Gianni, 2014).”
BackgroundModern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
Petrova, V., Arkhypov, I., Weber, R., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072367 · Cited by 54
“In another study, it was reported that the presence of Fcγ receptor-expressing macrophages within the TME is critical for the depletion of tumor-infiltrating Treg [78].”
BackgroundSon, J., Cho, J.-W., Park, H. J., Moon, J., Park, S., Lee, H., Lee, J., Kim, G., Park, S.-M., Lira, S. A., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0828 · Cited by 51
“In accordance with this hypothesis, anti–CTLA-4 given to melanoma patients bound to CTLA4 expressed by Tregs and induced the depletion of CTLA-4–expressing Tregs (50, 51).”
BackgroundDLL1 orchestrates CD8 + T cells to induce long-term vascular normalization and tumor regression
Zhang, N., Yin, R., Zhou, P., Liu, X., Fan, P., Qian, L., Li, D., Zhang, C., Zheng, X., Deng, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020057118 · Cited by 62
Avogadri, F., Zappasodi, R., Yang, A. S., Budhu, S., Malandro, N., Hirschhorn-Cymerman, D., Tiwari, S., Maughan, M. F., Olmsted, R. A., Wolchok, J. D., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0220 · Cited by 52
Self-citationOsaki, M., & Sakaguchi, S. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.004 · Cited by 52
Gao, J., He, Q., Subudhi, S., Aparicio, A., Zurita-Saavedra, A., Lee, D. H., Jimenez, C., Suarez-Almazor, M., & Sharma, P. (2015) · Oncogene · doi:10.1038/onc.2015.5 · Cited by 49
“Previous data have also indicated that anti-CTLA-4 can lead to decrease in regulatory T cells [35] which may lead to diminished immunosuppression and potentiation of irAEs.”
BackgroundSchliemann, C., Gutbrodt, K. L., Kerkhoff, A., Pohlen, M., Wiebe, S., Silling, G., Angenendt, L., Keßler, T., Mesters, R. M., Giovannoni, L., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0179 · Cited by 49
Overcoming Tumor-Mediated Immunosuppression
Schlößer, H., Theurich, S., Shimabukuro‐Vornhagen, A., Holtick, U., Stippel, D. L., & von Bergwelt‐Baildon, M. (2014) · Immunotherapy · doi:10.2217/imt.14.58 · Cited by 57
deLeeuw, R. J., Kroeger, D. R., Kost, S. E. F., Chang, P.-P., Webb, J. R., & Nelson, B. H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0146 · Cited by 54
Checkpoint Blockade for the Treatment of Advanced Melanoma
Callahan, M. K., Flaherty, C., & Postow, M. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_9 · Cited by 50
Chen, X., Takemoto, Y., Deng, H., Middelhoff, M. A., Friedman, R. A., Chu, T. H., Churchill, M., Ma, Y., Nagar, K. K., Tailor, Y. H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1290034 · Cited by 57
“Among the various subclasses of T cells, CD4C Tregs are suppressor T cells that modulate adaptive immune responses, maintaining tolerance to self-antigens and inhibiting cytotoxic CD8C T cell responses.(19,20) Treg function can be influenced by tumor myeloid cells through chemokine secretion,(17,21,22) and, in colon c…”
BackgroundMasterful Antibodies: Checkpoint Blockade
Lönberg, N., & Korman, A. J. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0057 · Cited by 52
“We and other laboratories reported (28, 29) that binding to FcgRs resulted in specific depletion of CTLA-4–high Treg cells at the tumor site, without lossof these cells in theperiphery.”
ResultSilva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 50
“To this end, the size of CD8+ clonal expansion has been found to precede such events, suggesting their detection in the peripheral circulation could represent a potential correlative biomarker.94 The second element provid- ing the rationale for CTLA-4 ICB is the proposed negative effect on immune suppressive Tregs.”
BackgroundInfluentialMartori, C., Sánchez-Moral, L., Paul, T., Pardo, J. C., Pous, A. F., de Porras, V. R., & Sarrias, M. (2022) · Cancers · doi:10.3390/cancers14020440 · Cited by 53
“revealed that reduction of Treg cells provoked by anti-CTLA-4 antibodies depend on FcγRIV-expressing macrophage-mediated cell depletion [77].”
BackgroundProgrammed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function
Araki, K., Youngblood, B., & Ahmed, R. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.78.019869 · Cited by 51
Structure and Optimization of Checkpoint Inhibitors
Picardo, S. L., Doi, J., & Hansen, A. R. (2019) · Cancers · doi:10.3390/cancers12010038 · Cited by 51
van den Bijgaart, R. J. E., Schuurmans, F., Fütterer, J. J., Verheij, M., Cornelissen, L. A. M., & Adema, G. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.617365 · Cited by 54
“Anti-CTLA-4 mAbs also cause intra-tumoral Treg depletion or modulation of their suppressive functions (87, 88).”
BackgroundTargeting CD8 + T-cell Tolerance for Cancer Immunotherapy
Jackson, S. R., Yuan, J., & Teague, R. M. (2014) · Immunotherapy · doi:10.2217/imt.14.51 · Cited by 51
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors
Tutt, A. L., James, S., Laversin, S. A., Tipton, T. R. W., Ashton‐Key, M., French, R. R., Hussain, K., Vaughan, A. T., Dou, L., Earley, A., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402988 · Cited by 53
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0588-4 · Cited by 50
Tuscano, J. M., Maverakis, E., Groshen, S. G., Tsao-Wei, D. D., Luxardi, G., Merleev, A. A., Beaven, A., DiPersio, J. F., Popplewell, L. L., Chen, R. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0438 · Cited by 48
“Ipilimumabmay also affect the tumor microenvironment by varied mechanisms, including the depletion of intratumoral CTLA-4–expressing regulatory T cells (12, 13), which has been correlated with response in patients with melanoma and colon cancer.”
BackgroundOkada, R., Kato, T., Furusawa, A., Inagaki, F. F., Wakiyama, H., Choyke, P. L., & Kobayashi, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000269 · Cited by 48
Wasiuk, A., Testa, J. S., Weidlick, J., Sisson, C., Vitale, L. A., Widger, J., Crocker, A., Thomas, L. J., Goldstein, J., Marsh, H. C., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700606 · Cited by 47
The New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 51
Self-citationEllmark, P., Mangsbo, S. M., Furebring, C., Norlén, P., & Tötterman, T. H. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1909-3 · Cited by 47
Metadata
- Authors
- Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., Peggs, K. S., Ravetch, J. V., Allison, J. P., & Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Rockefeller University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 3
- University College London (GB)
- Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK 6
- Department of Immunology, Juntendo University School of Medicine, 113-8421 Tokyo, Japan 5
- Corresponding author
- Allison, James P.
- Quezada, Sergio A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-07-29
- Volume
- 210
- Issue
- 9
- Pages
- 1695-1710
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3754863
- OpenAlex
- W2121080857
- Cited by
- 1,472
- References
- 60
- Citations by year
- 2026: 66 · 2025: 79 · 2024: 97 · 2023: 89 · 2022: 112 · 2021: 140 · 2020: 158 · 2019: 125 · 2018: 122 · 2017: 126 · 2016: 121 · 2015: 135 · 2014: 85 · 2013: 15
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- Canadian Institutes of Health Research
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, CTLA-4, regulatory T cells, melanoma, Fc gamma receptor, tumor-infiltrating macrophages, T cell depletion, tumor microenvironment, cancer immunotherapy, metastatic melanoma
- MeSH terms
- Animals, Cell Membrane, Clone Cells, Lymph Nodes, Lymphocyte Depletion, Melanoma, Mice, Inbred C57BL, Phagocytes, Signal Transduction, CD4 Antigens, Granulocyte-Macrophage Colony-Stimulating Factor, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Receptors, IgG, CD8-Positive T-Lymphocytes, Lymphocyte Count, Antibodies, Blocking, CD11b Antigen, T-Lymphocytes, Regulatory, Mice, TNF-Related Apoptosis-Inducing Ligand, Fas Ligand Protein, Tumor Microenvironment, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.